"Thesis in 4 Minutes" competition: the deadline to participate is extended

Concurs

The challenge consists in PhD students explaining their research thesis orally in under four minutes. All those interested can present their proposals from 28 February to 29 March.

25/02/2020

The competition “Tesi en 4 minuts”, organised by the UAB Doctoral School, offers PhD students the chance to explain their research in an oral presentation lasting a maximum of four minutes with easy to comprehend language.

Candidates can submit their proposals from 28 February to 22 March 29 March. The winning proposals will be selected by a committee of researchers and members of the Doctoral School's Permanent Board.

On 17 April 24 April all selected candidates will be notified via email. Oral presentations will take place on 14 May, in an event open to the public which will take place at the Graduation Hall (Sala de graus) of the Doctoral and Graduate School, as well as broadcast live on the university's website.

The first prize will include a cash prize of 800 euros and the second prize, 500 euros. A 200 euro cash prize will go to the best presentation voted by the audience.

More information

 

Related news

IMJIN WAR

First Database on the Imjin War Launched

ICREA researcher at the UAB Rebekah Clements has coordinated the launch of the first online database of the Imjin War, the largest war fought in the 16th century. This resource aims to be of great value to researchers specialising in the history of East Asia.

Descobreixen alteracions bioquŪmiques en els pacients amb la malaltia de Lesch-Nyhan

Biochemical alterations revealed in patients with Lesch-Nyhan disease

An international study by the Institute of Neuroscience, Emory University and Hospital Universitario La Paz shows that patients suffering from Lesch-Nyhan, a rare neurological disease, present biochemical alterations in skin cells, urine and cerebrospinal fluid. Published in the PNAS journal, the research will allow to advance in the study of this disease, which currently has no cure.

View all news